score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2963	54.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	READ_VARSCAN2	TCGA-DT-5265-01A-21D-1826-10	TCGA-DT-5265-10A-01D-1826-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.4255	47.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-AG-A015-01A-01W-A00K-09	TCGA-AG-A015-10A-01W-A00K-09
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.1832	131.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-AG-3878-01A-02W-0899-10	TCGA-AG-3878-10A-01W-0901-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.5217	115.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.3418	79.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-EI-6510-01A-11D-1733-10	TCGA-EI-6510-10A-01D-1733-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12C	0.2063	63.0	0.0	0.0		Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12C (Missense)	1	READ_VARSCAN2	TCGA-AG-4008-01A-01W-1073-09	TCGA-AG-4008-10A-01W-1073-09
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12C	0.1905	21.0	0.0	0.0		Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12C (Missense)	1	READ_VARSCAN2	TCGA-AG-3896-01A-01W-1073-09	TCGA-AG-3896-10A-01W-1073-09
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.4882	127.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-AH-6644-01A-21D-1826-10	TCGA-AH-6644-10A-01D-1826-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.5156	64.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.3137	51.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-BM-6198-01A-11D-1733-10	TCGA-BM-6198-10A-01D-1733-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.381	21.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-AG-A00Y-01A-02W-A00K-09	TCGA-AG-A00Y-10A-01W-A00K-09
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12C	0.3846	91.0	0.0	0.0		Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12C (Missense)	1	READ_VARSCAN2	TCGA-G5-6233-01A-11D-1733-10	TCGA-G5-6233-10A-01D-1733-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.6279	43.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-AG-3887-01A-01W-1073-09	TCGA-AG-3887-10A-01W-1073-09
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12C	0.3131	99.0	0.0	0.0		Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12C (Missense)	1	READ_VARSCAN2	TCGA-DC-6683-01A-11D-1826-10	TCGA-DC-6683-10A-01D-1826-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.4316	190.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-CI-6620-01A-11D-1826-10	TCGA-CI-6620-10A-01D-1826-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12C	0.6209	182.0	0.0	0.0		Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12C (Missense)	1	READ_VARSCAN2	TCGA-DY-A1H8-01A-21D-A152-10	TCGA-DY-A1H8-10A-01D-A152-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12C	0.4167	36.0	0.0	0.0		Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12C (Missense)	1	READ_VARSCAN2	TCGA-AG-A032-01A-01W-A00E-09	TCGA-AG-A032-10A-01W-A00E-09
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12C	0.3659	41.0	0.0	0.0		Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12C (Missense)	1	READ_VARSCAN2	TCGA-AG-A023-01A-01W-A00E-09	TCGA-AG-A023-10A-01W-A00E-09
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.25	40.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-AF-4110-01A-02D-1733-10	TCGA-AF-4110-10A-01D-1733-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.32	25.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	READ_VARSCAN2	TCGA-DC-6154-01A-31D-1924-10	TCGA-DC-6154-10A-01D-1924-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12D	0.7632	76.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-F5-6863-01A-11D-1924-10	TCGA-F5-6863-10A-01D-1924-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.5319	94.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	READ_VARSCAN2	TCGA-AF-6136-01A-11D-1826-10	TCGA-AF-6136-10A-01D-1826-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12C	0.6264	182.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12C (Missense)	1	READ_VARSCAN2	TCGA-AG-4022-01A-01D-1733-10	TCGA-AG-4022-10A-01D-1733-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12D	0.2571	105.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-DC-6682-01A-11D-1826-10	TCGA-DC-6682-10A-01D-1826-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12C	0.3626	171.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12C (Missense)	1	READ_VARSCAN2	TCGA-DC-5337-01A-01D-1657-10	TCGA-DC-5337-10A-01D-1657-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61H	0.3836	159.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61H (Missense)	1	READ_VARSCAN2	TCGA-AF-3913-01A-02W-1073-09	TCGA-AF-3913-11A-01W-1073-09
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G13R	0.8462	91.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G13R (Missense)	1	READ_VARSCAN2	TCGA-AG-3725-01A-11D-1733-10	TCGA-AG-3725-11A-01D-1733-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G13D	0.443	79.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G13D (Missense)	1	READ_VARSCAN2	TCGA-AF-A56N-01A-12D-A38X-10	TCGA-AF-A56N-10A-01D-A38X-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.G12D	0.3167	120.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.G12D (Missense)	1	READ_VARSCAN2	TCGA-F5-6465-01A-11D-1733-10	TCGA-F5-6465-10A-01D-1733-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546K	0.3175	63.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546K (Missense)	1	READ_VARSCAN2	TCGA-AG-A015-01A-01W-A00K-09	TCGA-AG-A015-10A-01W-A00K-09
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1957	46.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	READ_VARSCAN2	TCGA-AG-4015-01A-01W-1073-09	TCGA-AG-4015-10A-01W-1073-09
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.25	60.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	READ_VARSCAN2	TCGA-AH-6903-01A-11D-1924-10	TCGA-AH-6903-10A-01D-1924-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545G	0.2109	147.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545G (Missense)	1	READ_VARSCAN2	TCGA-AG-3878-01A-02W-0899-10	TCGA-AG-3878-10A-01W-0901-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.3946	185.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	READ_VARSCAN2	TCGA-AG-A016-01A-01W-A00K-09	TCGA-AG-A016-10A-01W-A00K-09
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.4433	97.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	READ_VARSCAN2	TCGA-AG-A008-01A-01W-A00K-09	TCGA-AG-A008-10A-01W-A00K-09
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546K	0.2176	216.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546K (Missense)	1	READ_VARSCAN2	TCGA-AH-6644-01A-21D-1826-10	TCGA-AH-6644-10A-01D-1826-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.127	189.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	READ_VARSCAN2	TCGA-AH-6544-01A-11D-1826-10	TCGA-AH-6544-10A-01D-1826-10
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.R389C	0.1355	155.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.R389C (Missense)	1	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.F294L	0.3056	72.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.F294L (Missense)	1	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.H540Q	0.3673	49.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.H540Q (Missense)	1	READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.F247L	0.38	100.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.F247L (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P753L	0.1566	83.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P753L (Missense)	1	READ_VARSCAN2	TCGA-DY-A1DF-01A-11D-A152-10	TCGA-DY-A1DF-10A-01D-A152-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.R98Q	0.4808	104.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R98Q (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E114K	0.4111	90.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E114K (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.R956Q	0.2107	261.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.R956Q (Missense)		READ_VARSCAN2	TCGA-AG-A01J-01A-01W-A00E-09	TCGA-AG-A01J-10A-01W-A00E-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH2	Missense	p.G421S	0.2188	32.0	0.0	0.0		Investigate Actionability	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Investigate Actionability	0	More frequent in Acute Myeloid Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					IDH2 p.G421S (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.E257D	0.2388	67.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.E257D (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.E257D	0.4301	93.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.E257D (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.R946Q	0.4263	190.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.R946Q (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH2	Missense	p.D279N	0.4359	39.0	0.0	0.0		Investigate Actionability	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Investigate Actionability	0	More frequent in Acute Myeloid Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					IDH2 p.D279N (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Frameshift	p.D725*	0.125	296.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.D725* (Frameshift)		READ_VARSCAN2	TCGA-AG-4009-01A-01W-1073-09	TCGA-AG-4009-10A-01W-1073-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.P137T	0.2456	57.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.P137T (Missense)		READ_VARSCAN2	TCGA-AG-3891-01A-01W-1073-09	TCGA-AG-3891-10A-01W-1073-09
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Nonsense	p.S851*	0.1127	71.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.S851* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Nonsense	p.R1170*	0.5	32.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.R1170* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D681Y	0.2381	63.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D681Y (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E289K	0.3577	123.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E289K (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.K770N	0.4096	83.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.K770N (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.K908T	0.3797	79.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.K908T (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.T440M	0.3922	51.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.T440M (Missense)	0	READ_VARSCAN2	TCGA-AF-4110-01A-02D-1733-10	TCGA-AF-4110-10A-01D-1733-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12S	0.3	130.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12S (Missense)	1	READ_VARSCAN2	TCGA-DC-6155-01A-11D-1657-10	TCGA-DC-6155-10A-01D-1657-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12A	0.2743	113.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12A (Missense)	1	READ_VARSCAN2	TCGA-AH-6903-01A-11D-1924-10	TCGA-AH-6903-10A-01D-1924-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.1188	101.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-AG-3731-01A-11D-1733-10	TCGA-AG-3731-11A-01D-1733-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.4274	248.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-AG-A020-01A-21W-A096-10	TCGA-AG-A020-11A-11W-A096-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.3774	106.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	READ_VARSCAN2	TCGA-AF-6655-01A-11D-1826-10	TCGA-AF-6655-10A-01D-1826-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.3431	102.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	READ_VARSCAN2	TCGA-F5-6571-01A-12D-1826-10	TCGA-F5-6571-10A-01D-1826-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.1594	69.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	READ_VARSCAN2	TCGA-AG-3902-01A-01W-1073-09	TCGA-AG-3902-10A-01W-1073-09
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.9149	94.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	READ_VARSCAN2	TCGA-DY-A1DF-01A-11D-A152-10	TCGA-DY-A1DF-10A-01D-A152-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.2063	63.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-AG-4008-01A-01W-1073-09	TCGA-AG-4008-10A-01W-1073-09
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A146T	0.7083	144.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A146T (Missense)	1	READ_VARSCAN2	TCGA-AG-3909-01A-01W-1073-09	TCGA-AG-3909-10A-01W-1073-09
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.2018	114.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-DC-6681-01A-11D-1826-10	TCGA-DC-6681-10A-01D-1826-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.4234	111.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-AH-6549-01A-11D-1826-10	TCGA-AH-6549-10A-01D-1826-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.4934	152.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-CL-5917-01A-11D-1657-10	TCGA-CL-5917-10A-01D-1657-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.5771	175.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	READ_VARSCAN2	TCGA-AG-A01W-01A-21W-A096-10	TCGA-AG-A01W-11A-11W-A096-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.4792	48.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-AG-A008-01A-01W-A00K-09	TCGA-AG-A008-10A-01W-A00K-09
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61H	0.3626	91.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61H (Missense)	1	READ_VARSCAN2	TCGA-AG-3742-01A-11D-1657-10	TCGA-AG-3742-11A-01D-1657-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.6122	147.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	READ_VARSCAN2	TCGA-AF-5654-01A-01D-1657-10	TCGA-AF-5654-10A-01D-1657-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.4674	92.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-EI-7002-01A-11D-1924-10	TCGA-EI-7002-10A-01D-1924-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.3361	122.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	READ_VARSCAN2	TCGA-F5-6702-01A-11D-1826-10	TCGA-F5-6702-10A-01D-1826-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A59T	0.2606	165.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A59T (Missense)	1	READ_VARSCAN2	TCGA-DC-6160-01A-11D-1657-10	TCGA-DC-6160-10A-01D-1657-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.4615	39.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-AG-4021-01A-01D-1733-10	TCGA-AG-4021-10A-01D-1733-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12S	0.6875	32.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12S (Missense)	1	READ_VARSCAN2	TCGA-AG-A014-01A-02W-A00K-09	TCGA-AG-A014-10A-01W-A00K-09
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12A	0.2427	103.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12A (Missense)	1	READ_VARSCAN2	TCGA-F5-6812-01A-11D-1826-10	TCGA-F5-6812-10A-01D-1826-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.3273	55.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-F5-6861-01A-11D-1924-10	TCGA-F5-6861-10A-01D-1924-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.6774	155.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-AF-6672-01A-11D-1826-10	TCGA-AF-6672-10A-01D-1826-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.6667	48.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-AG-3591-01A-01D-1733-10	TCGA-AG-3591-10A-01D-1733-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A146T	0.2622	164.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A146T (Missense)	1	READ_VARSCAN2	TCGA-AG-3901-01A-01W-1073-09	TCGA-AG-3901-10A-01W-1073-09
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.K117N	0.8029	274.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.K117N (Missense)	1	READ_VARSCAN2	TCGA-AG-3885-01A-01W-0899-10	TCGA-AG-3885-10A-01W-0901-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.3115	61.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	READ_VARSCAN2	TCGA-G5-6235-01A-11D-1733-10	TCGA-G5-6235-10A-01D-1733-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12S	0.7719	114.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12S (Missense)	1	READ_VARSCAN2	TCGA-G5-6572-01A-11D-1826-10	TCGA-G5-6572-10A-01D-1826-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.3077	104.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-AH-6544-01A-11D-1826-10	TCGA-AH-6544-10A-01D-1826-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.4	90.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-G5-6233-01A-11D-1733-10	TCGA-G5-6233-10A-01D-1733-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.4011	182.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	READ_VARSCAN2	TCGA-AG-3727-01A-01W-0899-10	TCGA-AG-3727-10A-01W-0901-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.7991	214.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-AG-3726-01A-02W-0899-10	TCGA-AG-3726-10A-01W-0901-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.2708	48.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-AG-A00C-01A-01W-A00K-09	TCGA-AG-A00C-10A-01W-A00K-09
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12A	0.5214	117.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12A (Missense)	1	READ_VARSCAN2	TCGA-EI-6881-01A-11D-1924-10	TCGA-EI-6881-10A-01D-1924-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.4634	82.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	READ_VARSCAN2	TCGA-EF-5830-01A-01D-1657-10	TCGA-EF-5830-10A-01D-1657-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.7647	68.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	READ_VARSCAN2	TCGA-EI-6512-01A-11D-1733-10	TCGA-EI-6512-10A-01D-1733-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61L	0.6762	105.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61L (Missense)	1	READ_VARSCAN2	TCGA-AG-A02X-01A-01W-A00E-09	TCGA-AG-A02X-10A-01W-A00E-09
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R250*	0.1765	51.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R250* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R1730*	0.2895	76.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R1730* (Nonsense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site	p.X1921_splice	0.3774	53.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.X1921_splice (Splice Site)		READ_VARSCAN2	TCGA-G5-6641-01A-11D-1826-10	TCGA-G5-6641-10A-01D-1826-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.E2304Gfs*69	0.4915	59.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.E2304Gfs*69 (Frameshift)		READ_VARSCAN2	TCGA-G5-6641-01A-11D-1826-10	TCGA-G5-6641-10A-01D-1826-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R1466*	0.4538	130.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R1466* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R1730*	0.3929	140.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R1730* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R250*	0.8221	208.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R250* (Nonsense)		READ_VARSCAN2	TCGA-AG-3727-01A-01W-0899-10	TCGA-AG-3727-10A-01W-0901-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R2849*	0.2512	434.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R2849* (Nonsense)		READ_VARSCAN2	TCGA-AG-3891-01A-01W-1073-09	TCGA-AG-3891-10A-01W-1073-09
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R912W	0.2877	73.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R912W (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.Q703H	0.3125	16.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.Q703H (Missense)		READ_VARSCAN2	TCGA-G5-6641-01A-11D-1826-10	TCGA-G5-6641-10A-01D-1826-10
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.P715S	0.2727	44.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.P715S (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.E49*	0.3465	127.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E49* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R177W	0.3667	30.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R177W (Missense)		READ_VARSCAN2	TCGA-DC-6683-01A-11D-1826-10	TCGA-DC-6683-10A-01D-1826-10
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.S3231*	0.3684	57.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S3231* (Nonsense)		READ_VARSCAN2	TCGA-EI-6513-01A-21D-1733-10	TCGA-EI-6513-10A-01D-1733-10
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.T328S	0.3478	23.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.T328S (Missense)		READ_VARSCAN2	TCGA-DC-5869-01A-01D-1657-10	TCGA-DC-5869-10A-01D-1657-10
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3952	167.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	READ_VARSCAN2	TCGA-AG-3894-01A-01W-1073-09	TCGA-AG-3894-10A-01W-1073-09
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.5932	118.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	READ_VARSCAN2	TCGA-CL-4957-01A-01D-1733-10	TCGA-CL-4957-10A-01D-1733-10
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4453	137.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	READ_VARSCAN2	TCGA-DC-6160-01A-11D-1657-10	TCGA-DC-6160-10A-01D-1657-10
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.5	198.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	READ_VARSCAN2	TCGA-AG-A01L-01A-01W-A00K-09	TCGA-AG-A01L-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.A146T	0.4545	22.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.A146T (Missense)		READ_VARSCAN2	TCGA-AG-3592-01A-02D-1733-10	TCGA-AG-3592-10A-01D-1733-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.R752S	0.2763	76.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.R752S (Missense)	0	READ_VARSCAN2	TCGA-AG-3731-01A-11D-1733-10	TCGA-AG-3731-11A-01D-1733-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.4727	55.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R1185*	0.1778	45.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1185* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.I87L	0.4615	26.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.I87L (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V842I	0.4054	74.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V842I (Missense)		READ_VARSCAN2	TCGA-AG-3902-01A-01W-1073-09	TCGA-AG-3902-10A-01W-1073-09
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.M205I	0.2174	23.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.M205I (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R521Q	0.303	66.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R521Q (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.G776V	0.4638	69.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.G776V (Missense)		READ_VARSCAN2	TCGA-AH-6644-01A-21D-1826-10	TCGA-AH-6644-10A-01D-1826-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V697L	0.4884	43.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V697L (Missense)		READ_VARSCAN2	TCGA-AG-3732-01A-11D-1657-10	TCGA-AG-3732-11A-01D-1657-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.2308	156.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V842I	0.9622	1165.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V842I (Missense)		READ_VARSCAN2	TCGA-AG-3898-01A-01W-1073-09	TCGA-AG-3898-10A-01W-1073-09
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.M60R	0.4122	131.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.M60R (Missense)		READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.E280K	0.9	150.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.E280K (Missense)		READ_VARSCAN2	TCGA-AG-A00Y-01A-02W-A00K-09	TCGA-AG-A00Y-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V842I	0.829	345.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V842I (Missense)		READ_VARSCAN2	TCGA-AF-3914-01A-01W-1073-09	TCGA-AF-3914-11A-01W-1073-09
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S1074N	0.1333	60.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S1074N (Missense)		READ_VARSCAN2	TCGA-AG-3726-01A-02W-0899-10	TCGA-AG-3726-10A-01W-0901-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D767G	0.227	141.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D767G (Missense)		READ_VARSCAN2	TCGA-AG-3891-01A-01W-1073-09	TCGA-AG-3891-10A-01W-1073-09
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.E7*	0.3469	98.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E7* (Nonsense)	1	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.E299*	0.3297	182.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E299* (Nonsense)	1	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.E299*	0.3073	192.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E299* (Nonsense)	1	READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.E7*	0.3617	235.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E7* (Nonsense)	1	READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.D67N	0.2653	49.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.D67N (Missense)	0	READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P733Q	0.4545	132.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.P733Q (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S71R	0.3298	94.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S71R (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.S71I	0.3404	94.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.S71I (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.E333A	0.411	146.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.E333A (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.F53V	0.2308	65.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.F53V (Missense)	0	READ_VARSCAN2	TCGA-EI-6506-01A-11D-1733-10	TCGA-EI-6506-10A-01D-1733-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R860I	0.1842	38.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R860I (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.F420L	0.4	50.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.F420L (Missense)		READ_VARSCAN2	TCGA-AF-6136-01A-11D-1826-10	TCGA-AF-6136-10A-01D-1826-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.Y479D	0.5474	95.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.Y479D (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E726K	0.2315	203.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E726K (Missense)	1	READ_VARSCAN2	TCGA-AH-6903-01A-11D-1924-10	TCGA-AH-6903-10A-01D-1924-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.D258N	0.5167	60.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.D258N (Missense)	1	READ_VARSCAN2	TCGA-AG-A020-01A-21W-A096-10	TCGA-AG-A020-11A-11W-A096-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.K337N	0.35	20.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.K337N (Missense)	1	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R88Q	0.5303	66.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R88Q (Missense)	1	READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546E	0.4373	670.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546E (Missense)	1	READ_VARSCAN2	TCGA-DC-6158-01A-11D-1657-10	TCGA-DC-6158-10A-01D-1657-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546R	0.5774	601.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546R (Missense)	1	READ_VARSCAN2	TCGA-AG-3742-01A-11D-1657-10	TCGA-AG-3742-11A-01D-1657-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R951C	0.3556	315.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R951C (Missense)	1	READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.V344G	0.2447	94.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.V344G (Missense)	1	READ_VARSCAN2	TCGA-AG-3901-01A-01W-1073-09	TCGA-AG-3901-10A-01W-1073-09
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R115P	0.4364	55.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R115P (Missense)	1	READ_VARSCAN2	TCGA-DY-A0XA-01A-11D-A152-10	TCGA-DY-A0XA-10A-01D-A152-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G106V	0.2941	51.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G106V (Missense)	1	READ_VARSCAN2	TCGA-CI-6622-01A-11D-1826-10	TCGA-CI-6622-10A-01D-1826-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.P471L	0.4688	96.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.P471L (Missense)	1	READ_VARSCAN2	TCGA-AG-3887-01A-01W-1073-09	TCGA-AG-3887-10A-01W-1073-09
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E418K	0.2551	98.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E418K (Missense)	1	READ_VARSCAN2	TCGA-AG-A00C-01A-01W-A00K-09	TCGA-AG-A00C-10A-01W-A00K-09
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R88Q	0.59	100.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R88Q (Missense)	1	READ_VARSCAN2	TCGA-AH-6897-01A-11D-1924-10	TCGA-AH-6897-10A-01D-1924-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546R	0.2308	104.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546R (Missense)	1	READ_VARSCAN2	TCGA-AG-3891-01A-01W-1073-09	TCGA-AG-3891-10A-01W-1073-09
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q723*	0.2	130.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q723* (Nonsense)		READ_VARSCAN2	TCGA-AG-3878-01A-02W-0899-10	TCGA-AG-3878-10A-01W-0901-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P224Rfs*8	0.2963	54.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P224Rfs*8 (Frameshift)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1989*	0.5	22.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1989* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.G948R	0.3973	73.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.G948R (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q802Sfs*15	0.3667	30.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q802Sfs*15 (Frameshift)		READ_VARSCAN2	TCGA-DY-A1DF-01A-11D-A152-10	TCGA-DY-A1DF-10A-01D-A152-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1989*	0.2222	27.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1989* (Nonsense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.D947N	0.3478	69.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.D947N (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.E275D	0.3125	48.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E275D (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.V1064A	0.2864	199.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.V1064A (Missense)		READ_VARSCAN2	TCGA-AG-3906-01A-01W-1073-09	TCGA-AG-3906-10A-01W-1073-09
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.K527N	0.3636	22.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K527N (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1989*	0.2264	53.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1989* (Nonsense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.R2236Cfs*38	0.3704	27.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R2236Cfs*38 (Frameshift)		READ_VARSCAN2	TCGA-AG-3726-01A-02W-0899-10	TCGA-AG-3726-10A-01W-0901-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.F2141Sfs*59	0.218	344.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F2141Sfs*59 (Frameshift)		READ_VARSCAN2	TCGA-AG-3891-01A-01W-1073-09	TCGA-AG-3891-10A-01W-1073-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.K224N	0.3103	116.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.K224N (Missense)	1	READ_VARSCAN2	TCGA-AG-3592-01A-02D-1733-10	TCGA-AG-3592-10A-01D-1733-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337H	0.4853	136.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337H (Missense)	1	READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465H	0.3889	54.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465H (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L1408I	0.197	66.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L1408I (Missense)	1	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.R478Q	0.25	40.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.R478Q (Missense)	0	READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.D167G	0.2105	57.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.D167G (Missense)	0	READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.W566L	0.7895	57.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.W566L (Missense)		READ_VARSCAN2	TCGA-AH-6549-01A-11D-1826-10	TCGA-AH-6549-10A-01D-1826-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S2812Y	0.4414	145.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S2812Y (Missense)	1	READ_VARSCAN2	TCGA-CL-5917-01A-11D-1657-10	TCGA-CL-5917-10A-01D-1657-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S582L	0.7064	109.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S582L (Missense)		READ_VARSCAN2	TCGA-AG-3742-01A-11D-1657-10	TCGA-AG-3742-11A-01D-1657-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.4538	119.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.A554T	0.4352	108.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.A554T (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.R142I	0.4	140.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.R142I (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.K239Q	0.3684	171.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.K239Q (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R179H	0.2667	15.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R179H (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S571Y	0.4467	150.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S571Y (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L942I	0.4015	274.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L942I (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R1150I	0.3778	225.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R1150I (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L1217M	0.3649	148.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L1217M (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L1408I	0.3137	102.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L1408I (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2147I	0.3039	102.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2147I (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2251I	0.3955	220.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2251I (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.6477	193.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		READ_VARSCAN2	TCGA-AG-3898-01A-01W-1073-09	TCGA-AG-3898-10A-01W-1073-09
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Frameshift	p.Q194Sfs*109	0.1746	63.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.Q194Sfs*109 (Frameshift)		READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465H	0.3422	339.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465H (Missense)		READ_VARSCAN2	TCGA-AG-3881-01A-01W-0899-10	TCGA-AG-3881-10A-01W-0901-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.N3003S	0.3604	111.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.N3003S (Missense)	1	READ_VARSCAN2	TCGA-F5-6813-01A-11D-1826-10	TCGA-F5-6813-10A-01D-1826-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.N2875S	0.3	70.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.N2875S (Missense)	1	READ_VARSCAN2	TCGA-EI-7004-01A-11D-1924-10	TCGA-EI-7004-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.6837	98.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		READ_VARSCAN2	TCGA-DC-6682-01A-11D-1826-10	TCGA-DC-6682-10A-01D-1826-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S978Y	0.1583	139.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S978Y (Missense)	1	READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2557V	0.1975	162.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2557V (Missense)	1	READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505C	0.4783	161.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505C (Missense)		READ_VARSCAN2	TCGA-AG-3885-01A-01W-0899-10	TCGA-AG-3885-10A-01W-0901-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D1682Y	0.2908	141.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D1682Y (Missense)	1	READ_VARSCAN2	TCGA-AG-3885-01A-01W-0899-10	TCGA-AG-3885-10A-01W-0901-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2039K	0.4352	108.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2039K (Missense)	1	READ_VARSCAN2	TCGA-AG-3885-01A-01W-0899-10	TCGA-AG-3885-10A-01W-0901-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.D600Y	0.4016	122.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.D600Y (Missense)		READ_VARSCAN2	TCGA-AG-A011-01A-01W-A00K-09	TCGA-AG-A011-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.G437R	0.1742	551.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.G437R (Missense)		READ_VARSCAN2	TCGA-AG-A011-01A-01W-A00K-09	TCGA-AG-A011-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.5397	63.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337C (Missense)	1	READ_VARSCAN2	TCGA-G5-6233-01A-11D-1733-10	TCGA-G5-6233-10A-01D-1733-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S195I	0.2514	179.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S195I (Missense)		READ_VARSCAN2	TCGA-AG-3728-01A-01W-0899-10	TCGA-AG-3728-10A-01W-0901-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465H	0.494	168.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465H (Missense)		READ_VARSCAN2	TCGA-EF-5830-01A-01D-1657-10	TCGA-EF-5830-10A-01D-1657-10
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.R170H	0.15	140.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.R170H (Missense)		READ_VARSCAN2	TCGA-AF-4110-01A-02D-1733-10	TCGA-AF-4110-10A-01D-1733-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.H580Y	0.3333	48.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.H580Y (Missense)		READ_VARSCAN2	TCGA-DC-5869-01A-01D-1657-10	TCGA-DC-5869-10A-01D-1657-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.L443F	0.3214	84.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.L443F (Missense)		READ_VARSCAN2	TCGA-DC-5869-01A-01D-1657-10	TCGA-DC-5869-10A-01D-1657-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.2653	49.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337C (Missense)	1	READ_VARSCAN2	TCGA-EI-6512-01A-11D-1733-10	TCGA-EI-6512-10A-01D-1733-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R759C	0.4177	79.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R759C (Missense)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P286R	0.3333	30.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P286R (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.A426V	0.2927	41.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.A426V (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.V411L	0.2581	31.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.V411L (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.L1044P	0.3529	17.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.L1044P (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.I878V	0.2203	59.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.I878V (Missense)		READ_VARSCAN2	TCGA-F5-6464-01A-11D-1733-10	TCGA-F5-6464-10A-01D-1733-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D2013N	0.3684	19.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D2013N (Missense)		READ_VARSCAN2	TCGA-AG-A01W-01A-21W-A096-10	TCGA-AG-A01W-11A-11W-A096-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.S459F	0.36	100.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.S459F (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.L852R	0.2051	39.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.L852R (Missense)		READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.S459F	0.3689	122.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.S459F (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.R335Qfs*2	0.6667	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R335Qfs*2 (Frameshift)		READ_VARSCAN2	TCGA-AG-3890-01A-01W-1073-09	TCGA-AG-3890-10A-01W-1073-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.V73Rfs*76	0.5882	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V73Rfs*76 (Frameshift)		READ_VARSCAN2	TCGA-DC-6155-01A-11D-1657-10	TCGA-DC-6155-10A-01D-1657-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.7391	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		READ_VARSCAN2	TCGA-AG-4015-01A-01W-1073-09	TCGA-AG-4015-10A-01W-1073-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X33_splice	0.4231	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X33_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-3731-01A-11D-1733-10	TCGA-AG-3731-11A-01D-1733-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E180*	0.5758	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E180* (Nonsense)		READ_VARSCAN2	TCGA-DC-4745-01A-01D-1733-10	TCGA-DC-4745-10A-01D-1733-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E171*	0.3929	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E171* (Nonsense)		READ_VARSCAN2	TCGA-F5-6864-01A-11D-1924-10	TCGA-F5-6864-10A-01D-1924-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L35Pfs*10	0.7373	236.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L35Pfs*10 (Frameshift)		READ_VARSCAN2	TCGA-AG-A026-01A-32W-A096-10	TCGA-AG-A026-10A-01W-A096-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.W53Mfs*4	0.6316	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.W53Mfs*4 (Frameshift)		READ_VARSCAN2	TCGA-EI-6885-01A-11D-1924-10	TCGA-EI-6885-10A-01D-1924-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.7609	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.5357	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		READ_VARSCAN2	TCGA-F5-6571-01A-12D-1826-10	TCGA-F5-6571-10A-01D-1826-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.2791	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.9524	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		READ_VARSCAN2	TCGA-DC-6154-01A-31D-1924-10	TCGA-DC-6154-10A-01D-1924-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.S94Cfs*30	0.4762	84.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S94Cfs*30 (Frameshift)		READ_VARSCAN2	TCGA-AF-6136-01A-11D-1826-10	TCGA-AF-6136-10A-01D-1826-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.V122Dfs*26	0.493	142.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V122Dfs*26 (Frameshift)		READ_VARSCAN2	TCGA-AG-4001-01A-02W-1073-09	TCGA-AG-4001-10A-01W-1073-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.K164Sfs*5	0.7273	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K164Sfs*5 (Frameshift)		READ_VARSCAN2	TCGA-AG-3732-01A-11D-1657-10	TCGA-AG-3732-11A-01D-1657-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.K319Afs*19	0.3816	76.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K319Afs*19 (Frameshift)		READ_VARSCAN2	TCGA-AG-3898-01A-01W-1073-09	TCGA-AG-3898-10A-01W-1073-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.8125	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		READ_VARSCAN2	TCGA-EI-6508-01A-11D-1733-10	TCGA-EI-6508-10A-01D-1733-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.S90Pfs*33	0.6667	93.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S90Pfs*33 (Frameshift)		READ_VARSCAN2	TCGA-AG-4009-01A-01W-1073-09	TCGA-AG-4009-10A-01W-1073-09
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.T211Ffs*4	0.6438	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T211Ffs*4 (Frameshift)		READ_VARSCAN2	TCGA-F5-6810-01A-11D-1826-10	TCGA-F5-6810-10A-01D-1826-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R342*	0.5732	82.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342* (Nonsense)		READ_VARSCAN2	TCGA-AF-A56K-01A-32D-A38X-10	TCGA-AF-A56K-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.F109Lfs*36	0.3333	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F109Lfs*36 (Frameshift)		READ_VARSCAN2	TCGA-DC-6160-01A-11D-1657-10	TCGA-DC-6160-10A-01D-1657-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X33_splice	0.4348	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X33_splice (Splice Site)		READ_VARSCAN2	TCGA-AF-2693-01A-02D-1733-10	TCGA-AF-2693-10A-01D-1733-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.5579	233.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		READ_VARSCAN2	TCGA-AG-A01Y-01A-41W-A096-10	TCGA-AG-A01Y-11A-11W-A096-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q136*	0.6316	19.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q136* (Nonsense)		READ_VARSCAN2	TCGA-DY-A0XA-01A-11D-A152-10	TCGA-DY-A0XA-10A-01D-A152-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.C124Ffs*47	0.5517	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C124Ffs*47 (Frameshift)		READ_VARSCAN2	TCGA-G5-6233-01A-11D-1733-10	TCGA-G5-6233-10A-01D-1733-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E287*	0.4815	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E287* (Nonsense)		READ_VARSCAN2	TCGA-DT-5265-01A-21D-1826-10	TCGA-DT-5265-10A-01D-1826-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.Y234Pfs*7	0.3095	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y234Pfs*7 (Frameshift)		READ_VARSCAN2	TCGA-CI-6620-01A-11D-1826-10	TCGA-CI-6620-10A-01D-1826-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X331_splice	0.4367	316.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X331_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-3883-01A-02W-0899-10	TCGA-AG-3883-10A-01W-0901-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.6512	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		READ_VARSCAN2	TCGA-EI-6881-01A-11D-1924-10	TCGA-EI-6881-10A-01D-1924-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X126_splice	0.375	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X126_splice (Splice Site)		READ_VARSCAN2	TCGA-AF-A56N-01A-12D-A38X-10	TCGA-AF-A56N-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P219Afs*3	0.3898	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P219Afs*3 (Frameshift)		READ_VARSCAN2	TCGA-AF-4110-01A-02D-1733-10	TCGA-AF-4110-10A-01D-1733-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E285*	0.8136	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285* (Nonsense)		READ_VARSCAN2	TCGA-AG-A02X-01A-01W-A00E-09	TCGA-AG-A02X-10A-01W-A00E-09
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.A56T	0.1413	92.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.A56T (Missense)		READ_VARSCAN2	TCGA-AH-6644-01A-21D-1826-10	TCGA-AH-6644-10A-01D-1826-10
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.T104I	0.2077	130.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.T104I (Missense)		READ_VARSCAN2	TCGA-DY-A0XA-01A-11D-A152-10	TCGA-DY-A0XA-10A-01D-A152-10
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.R483Q	0.3846	26.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.R483Q (Missense)		READ_VARSCAN2	TCGA-AG-3728-01A-01W-0899-10	TCGA-AG-3728-10A-01W-0901-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.5	38.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-CI-6624-01C-11D-1826-10	TCGA-CI-6624-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.P250L	0.4	60.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P250L (Missense)		READ_VARSCAN2	TCGA-CI-6619-01B-11D-1826-10	TCGA-CI-6619-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.A138V	0.5577	52.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A138V (Missense)		READ_VARSCAN2	TCGA-AG-3893-01A-01W-1073-09	TCGA-AG-3893-10A-01W-1073-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.5238	21.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		READ_VARSCAN2	TCGA-CI-6621-01A-11D-1826-10	TCGA-CI-6621-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.7838	37.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-AG-3592-01A-02D-1733-10	TCGA-AG-3592-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.9265	68.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-AG-A016-01A-01W-A00K-09	TCGA-AG-A016-10A-01W-A00K-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.564	172.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		READ_VARSCAN2	TCGA-AF-2687-01A-02D-1733-10	TCGA-AF-2687-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.C141R	0.5924	211.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C141R (Missense)		READ_VARSCAN2	TCGA-AG-A036-01A-12W-A096-10	TCGA-AG-A036-11A-11W-A096-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.4505	91.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.8559	118.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-AG-A020-01A-21W-A096-10	TCGA-AG-A020-11A-11W-A096-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.6744	43.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		READ_VARSCAN2	TCGA-EI-6509-01A-11D-1733-10	TCGA-EI-6509-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.P151S	0.6786	28.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151S (Missense)		READ_VARSCAN2	TCGA-DC-6157-01A-11D-1657-10	TCGA-DC-6157-10A-01D-1657-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.P278A	0.6864	236.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278A (Missense)		READ_VARSCAN2	TCGA-AG-3882-01A-01W-0899-10	TCGA-AG-3882-10A-01W-0901-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.Y205D	0.3333	48.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y205D (Missense)		READ_VARSCAN2	TCGA-AF-6655-01A-11D-1826-10	TCGA-AF-6655-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.1176	68.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		READ_VARSCAN2	TCGA-EI-6510-01A-11D-1733-10	TCGA-EI-6510-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.3404	47.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		READ_VARSCAN2	TCGA-AG-3902-01A-01W-1073-09	TCGA-AG-3902-10A-01W-1073-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.963	27.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		READ_VARSCAN2	TCGA-DY-A1DF-01A-11D-A152-10	TCGA-DY-A1DF-10A-01D-A152-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.P151H	0.5172	87.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151H (Missense)		READ_VARSCAN2	TCGA-AG-4008-01A-01W-1073-09	TCGA-AG-4008-10A-01W-1073-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.A159V	0.4889	45.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A159V (Missense)		READ_VARSCAN2	TCGA-AG-3896-01A-01W-1073-09	TCGA-AG-3896-10A-01W-1073-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R213Q	0.1667	42.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213Q (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.L194F	0.4375	112.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L194F (Missense)		READ_VARSCAN2	TCGA-AG-3906-01A-01W-1073-09	TCGA-AG-3906-10A-01W-1073-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.C275Y	0.4	40.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275Y (Missense)		READ_VARSCAN2	TCGA-F5-6464-01A-11D-1733-10	TCGA-F5-6464-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.7045	44.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		READ_VARSCAN2	TCGA-AH-6549-01A-11D-1826-10	TCGA-AH-6549-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.8393	56.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		READ_VARSCAN2	TCGA-CL-5917-01A-11D-1657-10	TCGA-CL-5917-10A-01D-1657-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.6053	38.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		READ_VARSCAN2	TCGA-F5-6863-01A-11D-1924-10	TCGA-F5-6863-10A-01D-1924-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.6176	102.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		READ_VARSCAN2	TCGA-AG-4022-01A-01D-1733-10	TCGA-AG-4022-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.4638	69.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		READ_VARSCAN2	TCGA-DC-6158-01A-11D-1657-10	TCGA-DC-6158-10A-01D-1657-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.6049	205.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		READ_VARSCAN2	TCGA-AG-A01W-01A-21W-A096-10	TCGA-AG-A01W-11A-11W-A096-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.I195T	0.7532	77.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I195T (Missense)		READ_VARSCAN2	TCGA-DC-4749-01A-01D-1733-10	TCGA-DC-4749-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.5238	42.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		READ_VARSCAN2	TCGA-AG-3742-01A-11D-1657-10	TCGA-AG-3742-11A-01D-1657-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.5714	35.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-DY-A1DC-01A-31D-A152-10	TCGA-DY-A1DC-10A-01D-A152-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.6875	80.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		READ_VARSCAN2	TCGA-CL-4957-01A-01D-1733-10	TCGA-CL-4957-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.1429	56.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.675	40.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-F5-6811-01A-11D-1826-10	TCGA-F5-6811-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.7931	29.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		READ_VARSCAN2	TCGA-EI-7002-01A-11D-1924-10	TCGA-EI-7002-10A-01D-1924-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.G266V	0.3793	29.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G266V (Missense)		READ_VARSCAN2	TCGA-F5-6702-01A-11D-1826-10	TCGA-F5-6702-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.92	25.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		READ_VARSCAN2	TCGA-DY-A1DD-01A-21D-A152-10	TCGA-DY-A1DD-10A-01D-A152-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.4074	27.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-F5-6813-01A-11D-1826-10	TCGA-F5-6813-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.Y205S	0.5686	51.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y205S (Missense)		READ_VARSCAN2	TCGA-AG-4021-01A-01D-1733-10	TCGA-AG-4021-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.V274L	0.6415	53.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V274L (Missense)		READ_VARSCAN2	TCGA-AG-A014-01A-02W-A00K-09	TCGA-AG-A014-10A-01W-A00K-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.P278T	0.3333	36.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278T (Missense)		READ_VARSCAN2	TCGA-F5-6812-01A-11D-1826-10	TCGA-F5-6812-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.V272G	0.2	30.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V272G (Missense)		READ_VARSCAN2	TCGA-F5-6812-01A-11D-1826-10	TCGA-F5-6812-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.G245S	0.4167	60.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245S (Missense)		READ_VARSCAN2	TCGA-DC-6682-01A-11D-1826-10	TCGA-DC-6682-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.G245D	0.2444	90.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245D (Missense)		READ_VARSCAN2	TCGA-AF-6672-01A-11D-1826-10	TCGA-AF-6672-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.I195F	0.4068	59.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I195F (Missense)		READ_VARSCAN2	TCGA-AF-6672-01A-11D-1826-10	TCGA-AF-6672-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.I195T	0.8475	59.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I195T (Missense)		READ_VARSCAN2	TCGA-AG-3591-01A-01D-1733-10	TCGA-AG-3591-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.S215I	0.7183	71.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S215I (Missense)		READ_VARSCAN2	TCGA-CI-6623-01B-11D-1826-10	TCGA-CI-6623-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.E286K	0.7108	83.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286K (Missense)		READ_VARSCAN2	TCGA-AG-A00Y-01A-02W-A00K-09	TCGA-AG-A00Y-10A-01W-A00K-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.6977	43.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-AG-A01N-01A-01W-A00E-09	TCGA-AG-A01N-10A-01W-A00E-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.7204	93.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-AF-3913-01A-02W-1073-09	TCGA-AF-3913-11A-01W-1073-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.G262V	0.7534	73.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G262V (Missense)		READ_VARSCAN2	TCGA-AG-3885-01A-01W-0899-10	TCGA-AG-3885-10A-01W-0901-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.26	50.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		READ_VARSCAN2	TCGA-AG-A011-01A-01W-A00K-09	TCGA-AG-A011-10A-01W-A00K-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R337S	0.3514	37.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R337S (Missense)		READ_VARSCAN2	TCGA-EI-6506-01A-11D-1733-10	TCGA-EI-6506-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.2821	39.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		READ_VARSCAN2	TCGA-EI-6506-01A-11D-1733-10	TCGA-EI-6506-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.L194R	0.4074	54.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L194R (Missense)		READ_VARSCAN2	TCGA-AH-6544-01A-11D-1826-10	TCGA-AH-6544-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.3216	171.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		READ_VARSCAN2	TCGA-AF-3914-01A-01W-1073-09	TCGA-AF-3914-11A-01W-1073-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.H193N	0.6619	139.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193N (Missense)		READ_VARSCAN2	TCGA-AG-3728-01A-01W-0899-10	TCGA-AG-3728-10A-01W-0901-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.C238Y	0.5526	38.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C238Y (Missense)		READ_VARSCAN2	TCGA-DC-6683-01A-11D-1826-10	TCGA-DC-6683-10A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.5909	22.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		READ_VARSCAN2	TCGA-AG-A032-01A-01W-A00E-09	TCGA-AG-A032-10A-01W-A00E-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.E286G	0.331	145.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286G (Missense)		READ_VARSCAN2	TCGA-AG-3726-01A-02W-0899-10	TCGA-AG-3726-10A-01W-0901-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.4815	108.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-AG-A00C-01A-01W-A00K-09	TCGA-AG-A00C-10A-01W-A00K-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.8235	34.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-AG-3725-01A-11D-1733-10	TCGA-AG-3725-11A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.F109C	0.7432	74.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F109C (Missense)		READ_VARSCAN2	TCGA-AH-6643-01A-11D-1826-10	TCGA-AH-6643-11A-01D-1826-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.6774	31.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		READ_VARSCAN2	TCGA-EI-6511-01A-11D-1733-10	TCGA-EI-6511-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.7317	41.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		READ_VARSCAN2	TCGA-EF-5830-01A-01D-1657-10	TCGA-EF-5830-10A-01D-1657-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.8519	27.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		READ_VARSCAN2	TCGA-AH-6897-01A-11D-1924-10	TCGA-AH-6897-10A-01D-1924-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.G245S	0.617	47.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245S (Missense)		READ_VARSCAN2	TCGA-EI-6883-01A-31D-1924-10	TCGA-EI-6883-10A-01D-1924-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.6522	46.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		READ_VARSCAN2	TCGA-AG-A01L-01A-01W-A00K-09	TCGA-AG-A01L-10A-01W-A00K-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.4815	27.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		READ_VARSCAN2	TCGA-CL-5918-01A-11D-1657-10	TCGA-CL-5918-10A-01D-1657-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R282W	1.0	24.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		READ_VARSCAN2	TCGA-DY-A1DG-01A-11D-A152-10	TCGA-DY-A1DG-10A-01D-A152-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.75	32.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		READ_VARSCAN2	TCGA-EI-6514-01A-11D-1733-10	TCGA-EI-6514-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.I232N	0.6818	66.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I232N (Missense)		READ_VARSCAN2	TCGA-AF-3911-01A-01D-1733-10	TCGA-AF-3911-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.E258G	0.6949	59.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E258G (Missense)		READ_VARSCAN2	TCGA-DC-5869-01A-01D-1657-10	TCGA-DC-5869-10A-01D-1657-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.4571	70.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		READ_VARSCAN2	TCGA-AF-2690-01A-02D-1733-10	TCGA-AF-2690-10A-01D-1733-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.4921	63.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		READ_VARSCAN2	TCGA-AF-A56L-01A-31D-A38X-10	TCGA-AF-A56L-10A-01D-A38X-10
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Missense	p.A138V	0.6667	24.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A138V (Missense)		READ_VARSCAN2	TCGA-EI-6512-01A-11D-1733-10	TCGA-EI-6512-10A-01D-1733-10
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.Q196H	0.1915	47.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.Q196H (Missense)		READ_VARSCAN2	TCGA-CI-6624-01C-11D-1826-10	TCGA-CI-6624-10A-01D-1826-10
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.F827L	0.2182	55.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.F827L (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.F828L	0.2061	131.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.F828L (Missense)		READ_VARSCAN2	TCGA-AG-3896-01A-01W-1073-09	TCGA-AG-3896-10A-01W-1073-09
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.H104R	0.5556	36.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.H104R (Missense)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.R616H	0.1628	172.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.R616H (Missense)		READ_VARSCAN2	TCGA-AG-3898-01A-01W-1073-09	TCGA-AG-3898-10A-01W-1073-09
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.P15L	0.1667	48.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.P15L (Missense)		READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.V797Cfs*19	0.5333	45.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.V797Cfs*19 (Frameshift)		READ_VARSCAN2	TCGA-AG-3878-01A-02W-0899-10	TCGA-AG-3878-10A-01W-0901-10
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Frameshift	p.Y162Efs*20	0.1651	745.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.Y162Efs*20 (Frameshift)		READ_VARSCAN2	TCGA-AG-A036-01A-12W-A096-10	TCGA-AG-A036-11A-11W-A096-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.V761M	0.3333	45.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.V761M (Missense)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.G822D	0.1481	27.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.G822D (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.K673N	0.3929	28.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.K673N (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Nonsense	p.R293*	0.4247	73.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.R293* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.W1065*	0.2794	68.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.W1065* (Nonsense)		READ_VARSCAN2	TCGA-DC-6681-01A-11D-1826-10	TCGA-DC-6681-10A-01D-1826-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.R315Q	0.2549	51.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R315Q (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.D34N	0.2157	51.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.D34N (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.N714H	0.1613	62.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.N714H (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.R209H	0.2893	121.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.R209H (Missense)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Nonsense	p.E784*	0.5385	13.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.E784* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E481D	0.3962	265.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E481D (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R1008C	0.4603	189.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R1008C (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.L808I	0.2593	27.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.L808I (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.S1100*	0.1564	179.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S1100* (Nonsense)		READ_VARSCAN2	TCGA-EI-6511-01A-11D-1733-10	TCGA-EI-6511-10A-01D-1733-10
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.K414N	0.4706	51.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.K414N (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.K469N	0.2857	70.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.K469N (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.L1583V	0.3191	47.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.L1583V (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R228Q	0.1845	103.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.R228Q (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.E484K	0.3514	111.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.E484K (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.F1578L	0.2192	146.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.F1578L (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.L245I	0.2016	258.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.L245I (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Splice Site	p.X287_splice	0.3661	112.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.X287_splice (Splice Site)	1	READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D1096N	0.1111	99.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D1096N (Missense)	0	READ_VARSCAN2	TCGA-CI-6624-01C-11D-1826-10	TCGA-CI-6624-10A-01D-1826-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D1096E	0.1146	96.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D1096E (Missense)	0	READ_VARSCAN2	TCGA-CI-6624-01C-11D-1826-10	TCGA-CI-6624-10A-01D-1826-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.T3401M	0.2812	32.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.T3401M (Missense)	0	READ_VARSCAN2	TCGA-AH-6903-01A-11D-1924-10	TCGA-AH-6903-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.L1390Ffs*13	0.1009	109.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.L1390Ffs*13 (Frameshift)	0	READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.G1100R	0.3889	90.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.G1100R (Missense)	1	READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.K722Q	0.4231	78.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K722Q (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.I1047M	0.2558	43.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.I1047M (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S1597Y	0.2353	68.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S1597Y (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2378A	0.2222	63.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2378A (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.R2494Q	0.3846	78.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.R2494Q (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2670L	0.3143	35.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2670L (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L3180R	0.42	50.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.L3180R (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.E572*	0.2692	130.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E572* (Nonsense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.K1767Nfs*10	0.1353	170.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K1767Nfs*10 (Frameshift)	0	READ_VARSCAN2	TCGA-AG-4008-01A-01W-1073-09	TCGA-AG-4008-10A-01W-1073-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E456D	0.5179	224.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E456D (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E1879D	0.38	100.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E1879D (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.K2017T	0.4451	173.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K2017T (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D2218Y	0.3902	164.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D2218Y (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2243Y	0.3687	179.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2243Y (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S3016Y	0.4607	89.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S3016Y (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E453D	0.3348	230.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E453D (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.V348M	0.2549	51.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.V348M (Missense)	0	READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.K1691Nfs*15	0.2286	140.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K1691Nfs*15 (Frameshift)	0	READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.F2349C	0.2409	465.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.F2349C (Missense)	0	READ_VARSCAN2	TCGA-AG-A00C-01A-01W-A00K-09	TCGA-AG-A00C-10A-01W-A00K-09
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.I1026Qfs*4	0.115	113.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.I1026Qfs*4 (Nonsense)	0	READ_VARSCAN2	TCGA-AF-3911-01A-01D-1733-10	TCGA-AF-3911-10A-01D-1733-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Splice Site	p.X613_splice	0.458	131.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.X613_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Frameshift	p.S261Rfs*6	0.4211	76.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 	Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.S261Rfs*6 (Frameshift)	0	READ_VARSCAN2	TCGA-DY-A1DD-01A-21D-A152-10	TCGA-DY-A1DD-10A-01D-A152-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.F334I	0.1	80.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.F334I (Missense)		READ_VARSCAN2	TCGA-F5-6813-01A-11D-1826-10	TCGA-F5-6813-10A-01D-1826-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.R156W	0.3026	76.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.R156W (Missense)	1	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.S328Y	0.4643	56.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.S328Y (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.R132I	0.1073	233.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.R132I (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S624L	0.2286	70.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S624L (Missense)	1	READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.I430V	0.2794	68.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.I430V (Missense)	1	READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.D142E	0.3161	155.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.D142E (Missense)	1	READ_VARSCAN2	TCGA-AG-3906-01A-01W-1073-09	TCGA-AG-3906-10A-01W-1073-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Nonsense	p.E287*	0.4301	193.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.E287* (Nonsense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.R753Q	0.4074	108.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.R753Q (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Nonsense	p.E181*	0.3782	349.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.E181* (Nonsense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.E19D	0.4172	151.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.E19D (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.R253Q	0.3714	70.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.R253Q (Missense)	0	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.K950T	0.4143	321.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.K950T (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S1089C	0.136	125.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S1089C (Missense)	1	READ_VARSCAN2	TCGA-F5-6813-01A-11D-1826-10	TCGA-F5-6813-10A-01D-1826-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Nonsense	p.Q227*	0.5735	68.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.Q227* (Nonsense)	1	READ_VARSCAN2	TCGA-DT-5265-01A-21D-1826-10	TCGA-DT-5265-10A-01D-1826-10
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.K302N	0.1842	38.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.K302N (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.M223I	0.1111	45.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.M223I (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.K167N	0.2069	29.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.K167N (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R374K	0.3636	66.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R374K (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S475Y	0.3448	29.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S475Y (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.K837N	0.2845	116.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.K837N (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R890H	0.2292	48.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R890H (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R779C	0.4691	81.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R779C (Missense)	0	READ_VARSCAN2	TCGA-F5-6571-01A-12D-1826-10	TCGA-F5-6571-10A-01D-1826-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R1049H	0.2727	33.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R1049H (Missense)	0	READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.R1062W	0.4634	41.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.R1062W (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.E366K	0.1163	43.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.E366K (Missense)		READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Nonsense	p.Q872*	0.161	236.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.Q872* (Nonsense)	0	READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.R628C	0.1235	81.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.R628C (Missense)		READ_VARSCAN2	TCGA-DY-A0XA-01A-11D-A152-10	TCGA-DY-A0XA-10A-01D-A152-10
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.D124E	0.2927	41.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.D124E (Missense)	0	READ_VARSCAN2	TCGA-G5-6572-01A-11D-1826-10	TCGA-G5-6572-10A-01D-1826-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Nonsense	p.E783*	0.2875	80.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.E783* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.K900N	0.1471	34.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.K900N (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Nonsense	p.E149*	0.3253	83.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.E149* (Nonsense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Nonsense	p.E782*	0.4206	214.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.E782* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.L1101I	0.4444	261.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.L1101I (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Guideline			Somatic Variant	TET2	Frameshift	p.T229Nfs*25	0.2787	61.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.T229Nfs*25 (Frameshift)		READ_VARSCAN2	TCGA-EI-6511-01A-11D-1733-10	TCGA-EI-6511-10A-01D-1733-10
Investigate Actionability	Clinical trial	Clinical evidence	Guideline	Somatic Variant	KRAS	Insertion	p.A11_G12dup	0.25	84.0	0.0	0.0		Investigate Actionability	Buparlisib + Trametinib	PI3K/AKT/mTOR inhibition + MEK inhibition	Targeted therapy	A phase 1b trial including 21 ovarian cancer patients demonstrated increased survival and an average PFS of 7 months when treated with a combination of buparlisib and trametinib (RP2D of buparlisib 60mg and trametinib 1.5mg daily).	Bedard PL, Tabernero J, Janku F, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015;21(4):730-8.	https://doi.org/10.1158/1078-0432.CCR-14-1814	Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	KRAS variants have been associated with decreased overall survival.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed June 13, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					KRAS p.A11_G12dup (Insertion)	1	READ_VARSCAN2	TCGA-CI-6622-01A-11D-1826-10	TCGA-CI-6622-10A-01D-1826-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Frameshift	p.E1119Rfs*27	0.3162	117.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.E1119Rfs*27 (Frameshift)		READ_VARSCAN2	TCGA-CI-6621-01A-11D-1826-10	TCGA-CI-6621-10A-01D-1826-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Frameshift	p.R534Vfs*9	0.3763	194.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.R534Vfs*9 (Frameshift)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.K409Q	0.4019	107.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.K409Q (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.K353N	0.2885	52.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.K353N (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.E181K	0.4098	61.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.E181K (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.K1233Q	0.3537	82.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.K1233Q (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R876C	0.3571	28.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R876C (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R461C	0.2885	52.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R461C (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.K414N	0.4271	96.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K414N (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.S666A	0.2273	66.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.S666A (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.L525I	0.3846	52.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.L525I (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.E358D	0.2632	38.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.E358D (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.R406Q	0.2603	73.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.R406Q (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.K1101N	0.2719	114.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.K1101N (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R833C	0.2969	64.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R833C (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.E351A	0.2842	95.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.E351A (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.R72C	0.2308	39.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.R72C (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E1318K	0.6628	258.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1318K (Missense)		READ_VARSCAN2	TCGA-DC-6158-01A-11D-1657-10	TCGA-DC-6158-10A-01D-1657-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Frameshift	p.K247Nfs*32	0.4314	102.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.K247Nfs*32 (Frameshift)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.N674Ifs*6	0.3704	135.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.N674Ifs*6 (Frameshift)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.I217L	0.4043	94.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.I217L (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.D379Y	0.4302	86.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.D379Y (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.R406Q	0.5373	67.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.R406Q (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Splice Site	p.X879_splice	0.5417	48.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.X879_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Nonsense	p.E604*	0.37	400.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.E604* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.E956D	0.4257	249.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.E956D (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.R1317W	0.364	250.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.R1317W (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Splice Site	p.X1239_splice	0.446	139.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.X1239_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.V1090A	0.4167	156.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.V1090A (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Nonsense	p.E771*	0.4079	228.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.E771* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.N412H	0.1974	152.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.N412H (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Nonsense	p.E586*	0.1468	218.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.E586* (Nonsense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.S400A	0.3411	129.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.S400A (Missense)		READ_VARSCAN2	TCGA-AG-3891-01A-01W-1073-09	TCGA-AG-3891-10A-01W-1073-09
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.R130Q	0.2	110.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130Q (Missense)	1	READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.R130Q	0.4154	325.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130Q (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.G165E	0.4006	322.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.G165E (Missense)	1	READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.Y68N	0.2308	26.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y68N (Missense)	1	READ_VARSCAN2	TCGA-AG-3901-01A-01W-1073-09	TCGA-AG-3901-10A-01W-1073-09
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.Q245P	0.2553	47.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q245P (Missense)	1	READ_VARSCAN2	TCGA-G5-6572-01A-11D-1826-10	TCGA-G5-6572-10A-01D-1826-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.G132V	0.5	58.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.G132V (Missense)	1	READ_VARSCAN2	TCGA-CI-6622-01A-11D-1826-10	TCGA-CI-6622-10A-01D-1826-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.A148S	0.4113	124.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.A148S (Missense)	1	READ_VARSCAN2	TCGA-DY-A1H8-01A-21D-A152-10	TCGA-DY-A1H8-10A-01D-A152-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Nonsense	p.R401*	0.3191	47.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R401* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Nonsense	p.R1209*	0.3659	41.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R1209* (Nonsense)		READ_VARSCAN2	TCGA-AF-6136-01A-11D-1826-10	TCGA-AF-6136-10A-01D-1826-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Nonsense	p.R401*	0.3692	65.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R401* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R1262C	0.1786	84.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1262C (Missense)		READ_VARSCAN2	TCGA-AF-2687-01A-02D-1733-10	TCGA-AF-2687-10A-01D-1733-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.E1387G	0.3516	91.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1387G (Missense)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.N339Ifs*3	0.3743	334.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.N339Ifs*3 (Frameshift)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.2243	107.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.P274Vfs*11	0.268	97.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.P274Vfs*11 (Frameshift)		READ_VARSCAN2	TCGA-CI-6619-01B-11D-1826-10	TCGA-CI-6619-10A-01D-1826-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R224*	0.2273	220.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R224* (Nonsense)		READ_VARSCAN2	TCGA-AH-6903-01A-11D-1924-10	TCGA-AH-6903-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R479*	0.625	16.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479* (Nonsense)		READ_VARSCAN2	TCGA-AF-2687-01A-02D-1733-10	TCGA-AF-2687-10A-01D-1733-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1200C	0.3289	76.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1200C (Missense)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.T859M	0.5833	24.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.T859M (Missense)		READ_VARSCAN2	TCGA-F5-6864-01A-11D-1924-10	TCGA-F5-6864-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.R321Q	0.3973	73.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.R321Q (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.D190Y	0.141	78.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.D190Y (Missense)	0	READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E579D	0.2069	29.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E579D (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.V46E	0.6605	162.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.V46E (Missense)	0	READ_VARSCAN2	TCGA-DY-A1DF-01A-11D-A152-10	TCGA-DY-A1DF-10A-01D-A152-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Splice Site	p.X374_splice	0.3125	288.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.X374_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-4008-01A-01W-1073-09	TCGA-AG-4008-10A-01W-1073-09
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.R321Q	0.2381	84.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.R321Q (Missense)	0	READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.S282*	0.194	67.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S282* (Nonsense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.E97*	0.2459	122.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.E97* (Nonsense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Nonsense	p.Q742*	0.303	33.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.Q742* (Nonsense)	0	READ_VARSCAN2	TCGA-AG-3742-01A-11D-1657-10	TCGA-AG-3742-11A-01D-1657-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.E369*	0.4305	223.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.E369* (Nonsense)		READ_VARSCAN2	TCGA-AF-5654-01A-01D-1657-10	TCGA-AF-5654-10A-01D-1657-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.S191*	0.2784	176.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S191* (Nonsense)		READ_VARSCAN2	TCGA-AF-5654-01A-01D-1657-10	TCGA-AF-5654-10A-01D-1657-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Frameshift	p.Q39Sfs*108	0.5246	61.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.Q39Sfs*108 (Frameshift)	0	READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R658*	0.412	216.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R658* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.R473Kfs*4	0.3019	106.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R473Kfs*4 (Frameshift)		READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Splice Site	p.X16_splice	0.32	50.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.X16_splice (Splice Site)	0	READ_VARSCAN2	TCGA-BM-6198-01A-11D-1733-10	TCGA-BM-6198-10A-01D-1733-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.Q492Rfs*6	0.4302	86.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Q492Rfs*6 (Frameshift)		READ_VARSCAN2	TCGA-CI-6620-01A-11D-1826-10	TCGA-CI-6620-10A-01D-1826-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.V134I	0.2963	54.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.V134I (Missense)		READ_VARSCAN2	TCGA-CI-6620-01A-11D-1826-10	TCGA-CI-6620-10A-01D-1826-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Splice Site	p.X473_splice	0.6847	314.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.X473_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-A00C-01A-01W-A00K-09	TCGA-AG-A00C-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R367*	0.457	221.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R367* (Nonsense)		READ_VARSCAN2	TCGA-AG-3725-01A-11D-1733-10	TCGA-AG-3725-11A-01D-1733-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R367*	0.9351	185.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R367* (Nonsense)		READ_VARSCAN2	TCGA-AH-6897-01A-11D-1924-10	TCGA-AH-6897-10A-01D-1924-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Splice Site	p.X319_splice	0.1074	121.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.X319_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-A01L-01A-01W-A00K-09	TCGA-AG-A01L-10A-01W-A00K-09
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R658*	0.3394	218.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R658* (Nonsense)		READ_VARSCAN2	TCGA-CL-5918-01A-11D-1657-10	TCGA-CL-5918-10A-01D-1657-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Splice Site	p.X473_splice	0.195	159.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.X473_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-3891-01A-01W-1073-09	TCGA-AG-3891-10A-01W-1073-09
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Nonsense	p.R150*	0.3529	68.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R150* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability		Clinical evidence	Guideline	Somatic Variant	TP53	Deletion	p.G108_H115del	0.3333	21.0	0.0	0.0									Investigate Actionability	Neoadjuvant chemoradiation	Chemotherapy + Radiation	Combination therapy	In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.	Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;	https://doi.org/10.1158/1078-0432.CCR-19-0908	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G108_H115del (Deletion)		READ_VARSCAN2	TCGA-EI-6513-01A-21D-1733-10	TCGA-EI-6513-10A-01D-1733-10
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.N217S	0.4348	23.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.N217S (Missense)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Splice Site	p.X151_splice	0.4872	39.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.X151_splice (Splice Site)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.E247K	0.3846	26.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.E247K (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.E353G	0.1951	41.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.E353G (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.R243H	0.1667	24.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.R243H (Missense)		READ_VARSCAN2	TCGA-DC-6681-01A-11D-1826-10	TCGA-DC-6681-10A-01D-1826-10
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.R679H	0.1379	29.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.R679H (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.R726C	0.3617	94.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.R726C (Missense)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.E247K	0.4648	71.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.E247K (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Splice Site	p.X518_splice	0.3721	43.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.X518_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.D190N	0.2756	127.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.D190N (Missense)		READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.A511V	0.3396	268.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.A511V (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Nonsense	p.E380*	0.4238	210.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E380* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.A124V	0.4362	94.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.A124V (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.D155Y	0.5283	106.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.D155Y (Missense)		READ_VARSCAN2	TCGA-AG-4015-01A-01W-1073-09	TCGA-AG-4015-10A-01W-1073-09
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.T468M	0.305	436.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.T468M (Missense)		READ_VARSCAN2	TCGA-AG-A036-01A-12W-A096-10	TCGA-AG-A036-11A-11W-A096-10
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.V285M	0.5263	19.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.V285M (Missense)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.E123D	0.2558	43.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.E123D (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.D445G	0.1304	23.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.D445G (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R321W	0.4182	55.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R321W (Missense)		READ_VARSCAN2	TCGA-F5-6571-01A-12D-1826-10	TCGA-F5-6571-10A-01D-1826-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.A1083S	0.3077	52.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.A1083S (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.R177Q	0.2612	134.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.R177Q (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.G503V	0.3395	162.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.G503V (Missense)		READ_VARSCAN2	TCGA-DY-A1DC-01A-31D-A152-10	TCGA-DY-A1DC-10A-01D-A152-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.H217R	0.2854	522.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.H217R (Missense)		READ_VARSCAN2	TCGA-AG-4001-01A-02W-1073-09	TCGA-AG-4001-10A-01W-1073-09
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Frameshift	p.Y239Pfs*4	0.351	151.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.Y239Pfs*4 (Frameshift)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R386I	0.4495	109.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R386I (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.Q588H	0.3696	46.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.Q588H (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.D184Y	0.3621	116.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.D184Y (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Nonsense	p.W222*	0.3785	251.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.W222* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.F1810V	0.4667	165.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.F1810V (Missense)		READ_VARSCAN2	TCGA-AG-A014-01A-02W-A00K-09	TCGA-AG-A014-10A-01W-A00K-09
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.F354L	0.125	104.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.F354L (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.K1034E	0.1975	81.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.K1034E (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Frameshift	p.N515Mfs*16	0.4677	62.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.N515Mfs*16 (Frameshift)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.W383G	0.3695	341.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.W383G (Missense)		READ_VARSCAN2	TCGA-AG-A020-01A-21W-A096-10	TCGA-AG-A020-11A-11W-A096-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.R474Q	0.1429	35.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R474Q (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.R587Q	0.3333	114.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R587Q (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.S1252Y	0.12	75.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.S1252Y (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Nonsense	p.Q419*	0.4085	71.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.Q419* (Nonsense)		READ_VARSCAN2	TCGA-EI-6510-01A-11D-1733-10	TCGA-EI-6510-10A-01D-1733-10
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Nonsense	p.R32*	0.7286	70.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R32* (Nonsense)		READ_VARSCAN2	TCGA-AG-3902-01A-01W-1073-09	TCGA-AG-3902-10A-01W-1073-09
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.R469H	0.2632	57.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R469H (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.K65N	0.2927	41.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.K65N (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.R792W	0.5405	37.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R792W (Missense)		READ_VARSCAN2	TCGA-AG-A008-01A-01W-A00K-09	TCGA-AG-A008-10A-01W-A00K-09
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Nonsense	p.S358*	0.3725	102.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.S358* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Frameshift	p.K883Sfs*10	0.5	76.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.K883Sfs*10 (Frameshift)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.S147Y	0.3614	249.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.S147Y (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.L263H	0.2687	67.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.L263H (Missense)		READ_VARSCAN2	TCGA-EI-7002-01A-11D-1924-10	TCGA-EI-7002-10A-01D-1924-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.L517F	0.315	508.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.L517F (Missense)		READ_VARSCAN2	TCGA-AG-3881-01A-01W-0899-10	TCGA-AG-3881-10A-01W-0901-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.L159P	0.4615	39.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.L159P (Missense)		READ_VARSCAN2	TCGA-DC-6682-01A-11D-1826-10	TCGA-DC-6682-10A-01D-1826-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.R515Q	0.1829	257.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R515Q (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.F1087C	0.1393	122.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.F1087C (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.A471V	0.4634	41.0	0.0	0.0																									RUNX1T1 p.A471V (Missense)		READ_VARSCAN2	TCGA-AG-A015-01A-01W-A00K-09	TCGA-AG-A015-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	NF1	Missense	p.S1786L	0.3793	116.0	0.0	0.0																									NF1 p.S1786L (Missense)		READ_VARSCAN2	TCGA-AG-A015-01A-01W-A00K-09	TCGA-AG-A015-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	RUNX1T1	Deletion	p.S108del	0.2683	82.0	0.0	0.0																									RUNX1T1 p.S108del (Deletion)		READ_VARSCAN2	TCGA-AG-3731-01A-11D-1733-10	TCGA-AG-3731-11A-01D-1733-10
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.R373*	0.1267	292.0	0.0	0.0																									RUNX1T1 p.R373* (Nonsense)		READ_VARSCAN2	TCGA-AG-A036-01A-12W-A096-10	TCGA-AG-A036-11A-11W-A096-10
Biologically Relevant				Somatic Variant	MYC	Deletion	p.S283del	0.3297	91.0	0.0	0.0																									MYC p.S283del (Deletion)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.T99M	0.4419	43.0	0.0	0.0																									PDGFB p.T99M (Missense)		READ_VARSCAN2	TCGA-EI-6882-01A-11D-1924-10	TCGA-EI-6882-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D533A	0.381	42.0	0.0	0.0																									ROS1 p.D533A (Missense)		READ_VARSCAN2	TCGA-F5-6864-01A-11D-1924-10	TCGA-F5-6864-10A-01D-1924-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.Y276F	0.2598	204.0	0.0	0.0																									RUNX1T1 p.Y276F (Missense)		READ_VARSCAN2	TCGA-EI-6509-01A-11D-1733-10	TCGA-EI-6509-10A-01D-1733-10
Biologically Relevant				Somatic Variant	EML4	Missense	p.V208F	0.1204	108.0	0.0	0.0																									EML4 p.V208F (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	TACC3	Missense	p.S399Y	0.4286	42.0	0.0	0.0																									TACC3 p.S399Y (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1506I	0.3583	120.0	0.0	0.0																									ROS1 p.R1506I (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D1450Y	0.1437	174.0	0.0	0.0																									ROS1 p.D1450Y (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R360I	0.1739	23.0	0.0	0.0																									ROS1 p.R360I (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R245I	0.1429	63.0	0.0	0.0																									ROS1 p.R245I (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R118Q	0.4182	55.0	0.0	0.0																									ROS1 p.R118Q (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	PMS2	Missense	p.S274L	0.3333	27.0	0.0	0.0																									PMS2 p.S274L (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ESRP1	Nonsense	p.E95*	0.3684	95.0	0.0	0.0																									ESRP1 p.E95* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E731K	0.4865	37.0	0.0	0.0																									FGFR2 p.E731K (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R446S	0.197	66.0	0.0	0.0																									FGFR2 p.R446S (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	FLI1	Nonsense	p.E218*	0.3614	83.0	0.0	0.0																									FLI1 p.E218* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	CDK4	Missense	p.R101M	0.381	21.0	0.0	0.0																									CDK4 p.R101M (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	RB1	Missense	p.E322K	0.3704	27.0	0.0	0.0																									RB1 p.E322K (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	RB1	Missense	p.R876C	0.125	56.0	0.0	0.0																									RB1 p.R876C (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.R222*	0.2174	23.0	0.0	0.0																									NTRK3 p.R222* (Nonsense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.K1632T	0.1525	59.0	0.0	0.0																									NF1 p.K1632T (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.L2367Q	0.4857	35.0	0.0	0.0																									NF1 p.L2367Q (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.R255W	0.2162	37.0	0.0	0.0																									IL12RB1 p.R255W (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	AURKA	Missense	p.E260D	0.382	89.0	0.0	0.0																									AURKA p.E260D (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ERG	Missense	p.R250I	0.4694	49.0	0.0	0.0																									ERG p.R250I (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ERG	Splice Site	p.X205_splice	0.2683	82.0	0.0	0.0																									ERG p.X205_splice (Splice Site)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	CRKL	Missense	p.E278K	0.1852	54.0	0.0	0.0																									CRKL p.E278K (Missense)		READ_VARSCAN2	TCGA-F5-6814-01A-31D-1924-10	TCGA-F5-6814-10A-01D-1924-10
Biologically Relevant				Somatic Variant	PMS2	Missense	p.M362I	0.1593	113.0	0.0	0.0																									PMS2 p.M362I (Missense)		READ_VARSCAN2	TCGA-AG-4008-01A-01W-1073-09	TCGA-AG-4008-10A-01W-1073-09
Biologically Relevant				Somatic Variant	FLI1	Missense	p.T427M	0.3415	41.0	0.0	0.0																									FLI1 p.T427M (Missense)		READ_VARSCAN2	TCGA-DC-6681-01A-11D-1826-10	TCGA-DC-6681-10A-01D-1826-10
Biologically Relevant				Somatic Variant	MLH1	Missense	p.R265C	0.2674	86.0	0.0	0.0																									MLH1 p.R265C (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.R853W	0.1714	35.0	0.0	0.0																									PDGFRB p.R853W (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R2184K	0.25	32.0	0.0	0.0																									ROS1 p.R2184K (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Biologically Relevant				Somatic Variant	PMS2	Nonsense	p.E411*	0.2667	60.0	0.0	0.0																									PMS2 p.E411* (Nonsense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D366G	0.3023	43.0	0.0	0.0																									RUNX1T1 p.D366G (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ESRP1	Nonsense	p.E142*	0.36	50.0	0.0	0.0																									ESRP1 p.E142* (Nonsense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.R192Q	0.2558	43.0	0.0	0.0																									NF1 p.R192Q (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.R440Q	0.2766	141.0	0.0	0.0																									NF1 p.R440Q (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Biologically Relevant				Somatic Variant	ERG	Missense	p.E129K	0.25	68.0	0.0	0.0																									ERG p.E129K (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.V215A	0.2742	62.0	0.0	0.0																									PDGFB p.V215A (Missense)		READ_VARSCAN2	TCGA-EI-6917-01A-11D-1924-10	TCGA-EI-6917-10A-01D-1924-10
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.R381C	0.3421	76.0	0.0	0.0																									LIMK2 p.R381C (Missense)		READ_VARSCAN2	TCGA-AG-3906-01A-01W-1073-09	TCGA-AG-3906-10A-01W-1073-09
Biologically Relevant				Somatic Variant	FLI1	Missense	p.T249M	0.1964	56.0	0.0	0.0																									FLI1 p.T249M (Missense)		READ_VARSCAN2	TCGA-AG-4022-01A-01D-1733-10	TCGA-AG-4022-10A-01D-1733-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1858T	0.4237	59.0	0.0	0.0																									ROS1 p.P1858T (Missense)		READ_VARSCAN2	TCGA-AF-5654-01A-01D-1657-10	TCGA-AF-5654-10A-01D-1657-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.T1865I	0.4071	140.0	0.0	0.0																									ROS1 p.T1865I (Missense)		READ_VARSCAN2	TCGA-DY-A1DC-01A-31D-A152-10	TCGA-DY-A1DC-10A-01D-A152-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R488C	0.1316	114.0	0.0	0.0																									RUNX1T1 p.R488C (Missense)		READ_VARSCAN2	TCGA-AH-6644-01A-21D-1826-10	TCGA-AH-6644-10A-01D-1826-10
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.A399T	0.3895	95.0	0.0	0.0																									FIP1L1 p.A399T (Missense)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Biologically Relevant				Somatic Variant	PDGFRB	Frameshift	p.P38Rfs*15	0.1527	131.0	0.0	0.0																									PDGFRB p.P38Rfs*15 (Frameshift)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Biologically Relevant				Somatic Variant	FGFR2	Frameshift	p.N184Tfs*9	0.3867	75.0	0.0	0.0																									FGFR2 p.N184Tfs*9 (Frameshift)		READ_VARSCAN2	TCGA-AG-A02N-01A-11D-A183-10	TCGA-AG-A02N-11A-11W-A096-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L1907F	0.4444	27.0	0.0	0.0																									MTOR p.L1907F (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	EML4	Splice Site	p.X781_splice	0.407	172.0	0.0	0.0																									EML4 p.X781_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	RAF1	Missense	p.V537I	0.3512	168.0	0.0	0.0																									RAF1 p.V537I (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	RAF1	Missense	p.R164Q	0.3945	109.0	0.0	0.0																									RAF1 p.R164Q (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	MLH1	Missense	p.I565M	0.375	88.0	0.0	0.0																									MLH1 p.I565M (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	MLH1	Missense	p.L658I	0.4153	118.0	0.0	0.0																									MLH1 p.L658I (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.R475W	0.5	166.0	0.0	0.0																									FIP1L1 p.R475W (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	PDGFRB	Nonsense	p.E97*	0.4808	52.0	0.0	0.0																									PDGFRB p.E97* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R2184I	0.3944	142.0	0.0	0.0																									ROS1 p.R2184I (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	ROS1	Missense	p.V1729L	0.3571	140.0	0.0	0.0																									ROS1 p.V1729L (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	ROS1	Missense	p.K1552T	0.345	171.0	0.0	0.0																									ROS1 p.K1552T (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	ROS1	Missense	p.K1163N	0.4171	187.0	0.0	0.0																									ROS1 p.K1163N (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.G610D	0.6	20.0	0.0	0.0																									FGFR1 p.G610D (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P183T	0.2973	185.0	0.0	0.0																									RUNX1T1 p.P183T (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	CD274	Missense	p.D276Y	0.3766	231.0	0.0	0.0																									CD274 p.D276Y (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E777K	0.4612	219.0	0.0	0.0																									FGFR2 p.E777K (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R664W	0.4574	129.0	0.0	0.0																									FGFR2 p.R664W (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.L551I	0.3103	58.0	0.0	0.0																									FGFR2 p.L551I (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R210Q	0.3878	98.0	0.0	0.0																									FGFR2 p.R210Q (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	FLI1	Missense	p.R355I	0.4167	60.0	0.0	0.0																									FLI1 p.R355I (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E280*	0.3402	194.0	0.0	0.0																									RB1 p.E280* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	RB1	Missense	p.R451C	0.3714	35.0	0.0	0.0																									RB1 p.R451C (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	NTRK3	Splice Site	p.X529_splice	0.365	137.0	0.0	0.0																									NTRK3 p.X529_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D495Y	0.449	49.0	0.0	0.0																									NTRK3 p.D495Y (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X244_splice	0.3974	78.0	0.0	0.0																									NF1 p.X244_splice (Splice Site)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R440*	0.3908	238.0	0.0	0.0																									NF1 p.R440* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	NF1	Missense	p.R440Q	0.4087	230.0	0.0	0.0																									NF1 p.R440Q (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	NF1	Missense	p.A1530D	0.3491	169.0	0.0	0.0																									NF1 p.A1530D (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Y1607*	0.3887	319.0	0.0	0.0																									NF1 p.Y1607* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	TPX2	Missense	p.K58N	0.3966	353.0	0.0	0.0																									TPX2 p.K58N (Missense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	LIMK2	Nonsense	p.R364*	0.3636	11.0	0.0	0.0																									LIMK2 p.R364* (Nonsense)		READ_VARSCAN2	TCGA-AG-A002-01A-01W-A00K-09	TCGA-AG-A002-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	RAF1	Missense	p.G366V	0.1919	99.0	0.0	0.0																									RAF1 p.G366V (Missense)		READ_VARSCAN2	TCGA-CL-4957-01A-01D-1733-10	TCGA-CL-4957-10A-01D-1733-10
Biologically Relevant				Somatic Variant	MDM2	Missense	p.V234L	0.2571	140.0	0.0	0.0																									MDM2 p.V234L (Missense)		READ_VARSCAN2	TCGA-CL-4957-01A-01D-1733-10	TCGA-CL-4957-10A-01D-1733-10
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.A126V	0.3014	73.0	0.0	0.0																									EWSR1 p.A126V (Missense)		READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.E219D	0.2391	92.0	0.0	0.0																									LIMK2 p.E219D (Missense)		READ_VARSCAN2	TCGA-EI-6507-01A-11D-1733-10	TCGA-EI-6507-10A-01D-1733-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.Q559K	0.3	50.0	0.0	0.0																									RUNX1T1 p.Q559K (Missense)		READ_VARSCAN2	TCGA-AG-4009-01A-01W-1073-09	TCGA-AG-4009-10A-01W-1073-09
Biologically Relevant				Somatic Variant	RB1	Missense	p.M695V	0.28	350.0	0.0	0.0																									RB1 p.M695V (Missense)		READ_VARSCAN2	TCGA-AG-3881-01A-01W-0899-10	TCGA-AG-3881-10A-01W-0901-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.R1204W	0.2857	98.0	0.0	0.0																									NF1 p.R1204W (Missense)		READ_VARSCAN2	TCGA-F5-6813-01A-11D-1826-10	TCGA-F5-6813-10A-01D-1826-10
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R640Q	0.3864	88.0	0.0	0.0																									BRD4 p.R640Q (Missense)		READ_VARSCAN2	TCGA-AG-4021-01A-01D-1733-10	TCGA-AG-4021-10A-01D-1733-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R394W	0.2784	194.0	0.0	0.0																									RUNX1T1 p.R394W (Missense)		READ_VARSCAN2	TCGA-AF-2693-01A-02D-1733-10	TCGA-AF-2693-10A-01D-1733-10
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.N254S	0.1863	102.0	0.0	0.0																									NTRK2 p.N254S (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Biologically Relevant				Somatic Variant	NF1	Missense	p.Q963H	0.1099	355.0	0.0	0.0																									NF1 p.Q963H (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.L3F	0.1731	156.0	0.0	0.0																									TMPRSS2 p.L3F (Missense)		READ_VARSCAN2	TCGA-AG-3892-01A-01D-1989-10	TCGA-AG-3892-10A-01W-1073-09
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P593L	0.44	50.0	0.0	0.0																									RUNX1T1 p.P593L (Missense)		READ_VARSCAN2	TCGA-AG-A01N-01A-01W-A00E-09	TCGA-AG-A01N-10A-01W-A00E-09
Biologically Relevant				Somatic Variant	NF1	Missense	p.M1285I	0.1687	83.0	0.0	0.0																									NF1 p.M1285I (Missense)		READ_VARSCAN2	TCGA-G5-6235-01A-11D-1733-10	TCGA-G5-6235-10A-01D-1733-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.L486Ifs*6	0.5043	117.0	0.0	0.0																									RB1 p.L486Ifs*6 (Frameshift)		READ_VARSCAN2	TCGA-G5-6572-01A-11D-1826-10	TCGA-G5-6572-10A-01D-1826-10
Biologically Relevant				Somatic Variant	PMS2	Missense	p.H139N	0.1053	57.0	0.0	0.0																									PMS2 p.H139N (Missense)		READ_VARSCAN2	TCGA-G5-6233-01A-11D-1733-10	TCGA-G5-6233-10A-01D-1733-10
Biologically Relevant				Somatic Variant	POT1	Missense	p.L559F	0.472	125.0	0.0	0.0																									POT1 p.L559F (Missense)		READ_VARSCAN2	TCGA-DT-5265-01A-21D-1826-10	TCGA-DT-5265-10A-01D-1826-10
Biologically Relevant				Somatic Variant	LIMK2	Splice Site	p.X6_splice	0.4333	30.0	0.0	0.0																									LIMK2 p.X6_splice (Splice Site)		READ_VARSCAN2	TCGA-DT-5265-01A-21D-1826-10	TCGA-DT-5265-10A-01D-1826-10
Biologically Relevant				Somatic Variant	POLE2	Missense	p.P380S	0.434	53.0	0.0	0.0																									POLE2 p.P380S (Missense)		READ_VARSCAN2	TCGA-AG-3887-01A-01W-1073-09	TCGA-AG-3887-10A-01W-1073-09
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G314E	0.4118	17.0	0.0	0.0																									COL1A1 p.G314E (Missense)		READ_VARSCAN2	TCGA-AG-3725-01A-11D-1733-10	TCGA-AG-3725-11A-01D-1733-10
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.T233M	0.6235	85.0	0.0	0.0																									PDGFB p.T233M (Missense)		READ_VARSCAN2	TCGA-AH-6643-01A-11D-1826-10	TCGA-AH-6643-11A-01D-1826-10
Biologically Relevant				Somatic Variant	BRD4	Missense	p.L1066P	0.3654	52.0	0.0	0.0																									BRD4 p.L1066P (Missense)		READ_VARSCAN2	TCGA-EI-6511-01A-11D-1733-10	TCGA-EI-6511-10A-01D-1733-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.T332M	0.375	32.0	0.0	0.0																									NTRK3 p.T332M (Missense)		READ_VARSCAN2	TCGA-AG-A01L-01A-01W-A00K-09	TCGA-AG-A01L-10A-01W-A00K-09
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.R266*	0.515	301.0	0.0	0.0																									RUNX1T1 p.R266* (Nonsense)		READ_VARSCAN2	TCGA-CL-5918-01A-11D-1657-10	TCGA-CL-5918-10A-01D-1657-10
Biologically Relevant				Somatic Variant	PMS2	Nonsense	p.K614*	0.5645	124.0	0.0	0.0																									PMS2 p.K614* (Nonsense)		READ_VARSCAN2	TCGA-AG-3891-01A-01W-1073-09	TCGA-AG-3891-10A-01W-1073-09
Biologically Relevant				Somatic Variant	FGFR1	Splice Site	p.X150_splice	0.7339	109.0	0.0	0.0																									FGFR1 p.X150_splice (Splice Site)		READ_VARSCAN2	TCGA-AF-A56L-01A-31D-A38X-10	TCGA-AF-A56L-10A-01D-A38X-10
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH6 p.E1119Rfs*27 (Frameshift), MSH2 p.R534Vfs*9 (Frameshift), PRDM2 p.R1687* (Nonsense), ACVR2A p.E232* (Nonsense), ESRP1 p.E95* (Nonsense), PMS2 p.E411* (Nonsense), ESRP1 p.E142* (Nonsense), RNF43 p.E742Gfs*5 (Frameshift), JAK1 p.N339Ifs*3 (Frameshift), MSH6 p.K247Nfs*32 (Frameshift), ACVR2A p.D96Tfs*54 (Frameshift), ACVR2A p.K437Efs*19 (Frameshift), MSH2 p.X879_splice (Splice Site), MSH6 p.E604* (Nonsense), ACVR2A p.E214* (Nonsense), ACVR2A p.E510* (Nonsense), DOCK3 p.E95* (Nonsense), POLE p.R150* (Nonsense), JAK1 p.K860Nfs*16 (Frameshift), MSH3 p.K383Gfs*20 (Frameshift), RNF43 p.E43Nfs*8 (Frameshift), RNF43 p.K45Sfs*25 (Frameshift), MSH3 p.A59_A60insPPAPPA (Insertion), ACVR2A p.X273_splice (Splice Site), PMS2 p.K614* (Nonsense)																													Supporting variants: MSH6 p.E1119Rfs*27 (Frameshift), MSH2 p.R534Vfs*9 (Frameshift), PRDM2 p.R1687* (Nonsense), ACVR2A p.E232* (Nonsense), ESRP1 p.E95* (Nonsense), PMS2 p.E411* (Nonsense), ESRP1 p.E142* (Nonsense), RNF43 p.E742Gfs*5 (Frameshift), JAK1 p.N339Ifs*3 (Frameshift), MSH6 p.K247Nfs*32 (Frameshift), ACVR2A p.D96Tfs*54 (Frameshift), ACVR2A p.K437Efs*19 (Frameshift), MSH2 p.X879_splice (Splice Site), MSH6 p.E604* (Nonsense), ACVR2A p.E214* (Nonsense), ACVR2A p.E510* (Nonsense), DOCK3 p.E95* (Nonsense), POLE p.R150* (Nonsense), JAK1 p.K860Nfs*16 (Frameshift), MSH3 p.K383Gfs*20 (Frameshift), RNF43 p.E43Nfs*8 (Frameshift), RNF43 p.K45Sfs*25 (Frameshift), MSH3 p.A59_A60insPPAPPA (Insertion), ACVR2A p.X273_splice (Splice Site), PMS2 p.K614* (Nonsense)		READ_VARSCAN2		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.911																													COSMIC Signature (version 2) 1 (91%)		READ_VARSCAN2		
